Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Pivikto 200mg+50mg Tablet
Manufacturer/Marketed By : NOVARTIS INDIA LTD
$384.04 $362.05
Sidmex Inovia offers bulk export supply of Pivikto 200mg+50mg Tablet (ALPELISIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain shipping and tenders:...
ALPELISIB
Active Pharmaceutical Ingredient
Pivikto 200mg+50mg Tablet
$384.04
$362.05
Sidmex Inovia offers bulk export supply of Pivikto 200mg+50mg Tablet (ALPELISIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.
Documents, cold-chain shipping and tenders: see our Export FAQ.
Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada
Related products we supply: Pivikto 200mg Tablet
Pivikto 200mg + 50mg tablet contains the active constituent Alpelisib. It is an anticancer agent that belongs to the class of medications called PI3K (phosphatidylinositol-3-kinase) inhibitors. It is used in combination with other anticancer medication to treat a certain type of breast cancer that has spread to nearby tissues or other parts of the body in women who have already gone through menopause or in men whose cancer got worse during or after certain other treatments. It is also used to treat those who have certain types of PIK3CA-related overgrowth spectrum (PROS; a genetic condition that causes overgrowth and abnormalities in certain body tissues). Do not take Pivikto 200mg + 50mg if you are allergic to Alpelisib or other ingredients in the medicine. Inform your physician if you have high levels of sugar in your blood or diabetes, bone disease, symptoms of skin rash, blistering of the lips, eyes, or mouth, skin peeling, fever, and red skin. Report to your doctor if you face any symptoms of rash, itching, hives, breathlessness, shortness of breath, wheezing, cough, low blood pressure, or discoloration of lips, tongue, or skin. This medicine is not recommended to be used in children and in adolescents under 18 years of age.
Active Pharmaceutical Ingredient
Uses
• HER2- negative Breast cancer
Benefits
Pivikto 200mg + 50mg is a kinase inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-alpha. In breast cancer cell cells, PI3K inhibition by this medicine induces an increase in estrogen receptor transcription. These enzymes help cancer cells to grow and multiply. By blocking their action, it can reduce cancer growth and spread and help destroy cancer cells.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Cellulitis
• Hyperglycemia
• Diarrhea
• Hypersensitivity reactions
• Pneumonitis
• Dehydration
• Angioedema
Common Side Effects
• Hair loss
• Decreased weight
• Decreased appetite
• Nausea, vomiting
• Tiredness
How To Use
Your doctor will decide the dose and duration of Pivikto 200mg + 50mg based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, immediately after food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. If you cannot swallow the tablet, mix the tablets into a glass of water as per doctor advice.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Pivikto 200mg + 50mg because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
• Alcohol: It is not known whether it is safe to consume alcohol with Pivikto 200mg + 50mg. Please consult your doctor.
• Liver: Pivikto 200mg + 50mg is safe to use in patients with liver problems. There is no need for dose adjustments. Inform your physician if you have any liver disease before initiating the therapy.
• Lungs: It is unknown whether Pivikto 200mg + 50mg can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
• Driving: Pivikto 200mg + 50mg may alter your ability to drive and operate heavy machinery. The treatment may cause tiredness hence avoid activities after taking the medicine.
• Pregnancy: Do not take Pivikto 200mg + 50mg if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment. Use effective contraception during the treatment and for 1 week after the last dose.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.